Alexander Stoeck

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

25h-index4.4kcitations61works31.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(9), Developmental Biology and Gene Regulation(7), Drug Transport and Resistance Mechanisms(7), Cell Adhesion Molecules Research(7), Salivary Gland Tumors Diagnosis and Treatment(7)

Publications61 total

Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS<sup>G12C</sup> Inhibitor
Journal of Medicinal Chemistry·2024· 31 cited
Abstract B074: Discovery of MK-1084, a low dose selective clinical stage KRAS G12C inhibitor
Molecular Cancer Therapeutics·2023· 1 cited
Supplementary Figures S1 - S7 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Data from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Figures 1-4; Supplementary Tables 1 &amp; 2 from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
2023Open Access
Data from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
2023Open Access
Supplementary Methods from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Table S9 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Tables S1 - S8 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Figures S1 - S7 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Data from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Data from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
2023Open Access
Supplementary Figure Legends from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
2023Open Access
Supplementary Methods from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Figure Legends from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
2023Open Access
Supplementary Table S9 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Figures 1-4; Supplementary Tables 1 &amp; 2 from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
2023Open Access
Supplementary Table S10 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Tables S1 - S8 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Table S10 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Brian B. Haines(14), Peter Altevogt(13), Serguei Lejnine(13), Theresa Zhang(13), Tian‐Li Wang(12), Paul Gutwein(10), Hongfang Wang(9), Michael Kluk(9), Birgit Knoechel(9), Jon C. Aster(9), Andrew Truong(8), Chongzhi Zang(8), Philip W. Garrett-Engele(8), Jason Laskey(8), Christopher A. Moskaluk(8), Leigh Zawel(8), Stephen E. Fawell(8), Brandon E. Kremer(8), B Bernstein(8), Warren S. Pear(8)